TABLE 3.

Evaluation of αGP25-200 and αP23 formulation candidate MAbs for inhibition of MAb 3E2 binding

MAb-1	Antigen specificity	Epitope compositiona	Binding of biotinylated 3E2 (MAb-2) (A405)b
3E2	CSL	C	0.07 ± 0.01
3H2	GP25-200	C	1.04 ± 0.04
1B3	GP25-200	C	1.01 ± 0.03
1C5	GP25-200	C	1.14 ± 0.09
2F6	GP25-200	P	1.03 ± 0.11
3D9	GP25-200	C	1.06 ± 0.05
4D10	GP25-200	P	1.19 ± 0.02
4E11	GP25-200	C	1.09 ± 0.06
4H7	GP25-200	P	1.08 ± 0.07
4H9	GP25-200	C	1.16 ± 0.05
1E10	P23	P	1.00 ± 0.02
4C11	P23	NDc	0.97 ± 0.06
5B9	P23	ND	1.08 ± 0.03
IgM isotype control			1.31 ± 0.04
IgG1 isotype control			1.11 ± 0.08

^aP, peptide; C, carbohydrate or carbohydrate-dependent (based on susceptibility to periodate and proteinase K). 

^bMeans and standard deviations from six replicates. 

^cND, not determined.